Skip to content
Clinical ResearchResearch compound

CJC‑1295

Experimental long-acting peptide that raises growth hormone (GH) levels; only small studies in humans.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

CJC-1295 vial

DETAILED OVERVIEW

What is CJC-1295?

CJC-1295 is an experimental peptide, a short protein chain, that is a modified version of GHRH, the natural hormone that releases growth hormone. It was modified so that it binds to one of the proteins in the blood, so it breaks down much more slowly and works for days instead of minutes.

In a clinical trial, growth hormone (GH) levels rose 2–10 times, and levels of IGF-1, a hormone that promotes growth, stayed raised for days. Only a few small studies have been done in humans, so there is still little data to judge its effects and safety.

Type

Modified growth hormone-releasing hormone, long-acting

Structure

30 aa + DAC (maleimidopropionyl-D-Lys)

Molecular weight

~3647 Da (DAC) / ~3367 Da (no-DAC)

Target area

GH/IGF-1

Storage

2–8°C (reconstituted)

Stability

25–30 days (reconstituted)

Growth hormone release

The peptide acts on pituitary GHRH or GHS receptors, producing a physiological, pulsatile GH release, unlike synthetic rHGH, which keeps levels flat and leads to desensitization. IGF-1 rises into the upper-normal range, driving recovery, muscle protein synthesis, lipolysis and skin quality. Deep-sleep phases lengthen; collagen and bone-matrix synthesis activate. The effect is reversible and does not suppress the endogenous GH axis.

Data console

Lab data

ClassificationModified growth hormone-releasing hormone, long-acting
Structure30 aa + DAC (maleimidopropionyl-D-Lys)
Molecular weight~3647 Da (DAC) / ~3367 Da (no-DAC)
Target areaGH/IGF-1
Storage2–8°C (reconstituted)
Stability25–30 days (reconstituted)

Research indications

Investigated uses and mechanisms

Growth hormone release

Mimics physiological pulsatile GH secretion; IGF-1 rise.

Recovery & body comp

Muscle mass gain, fat reduction, post-workout recovery.

Sleep quality

Deep-sleep (N3) phases lengthen.

Reconstitution

How to prepare, step by step

Important

Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.

  1. 01

    Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.

  2. 02

    Wipe both vial stoppers with an alcohol swab.

  3. 03

    Draw 2 ml of BAC water into a sterile syringe (typical for the 2 mg vial).

  4. 04

    Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.

  5. 05

    Swirl gently in a circular motion until dissolved (~30 s), do not shake.

  6. 06

    Wait for the solution to become clear. If sediment or discoloration appears, discard it.

  7. 07

    Label the vial with reconstitution date and concentration.

  8. 08

    Store at 2–8 °C, protected from light. Inspect visually before each use.

Quality indicators

How to recognize a pure peptide

Purity markers

4
  • White / off-white powder

    Typical appearance of sterile lyophilized peptide.

  • Comes with COA (Certificate of Analysis)

    Independent lab analysis, ≥98% purity.

  • Intact, sealed vial

    Rubber stopper + aluminum crimp intact, ensuring sterility.

  • Dissolves clear

    Clear solution after reconstitution, no sediment.

Use caution

1
  • Storage temperature

    Extended room-temp exposure may reduce potency.

Do not use

2
  • Discoloration / sediment

    Yellow, cloudy or particulate solution, indicates degradation, do not use.

  • Damaged packaging

    Cracked vial or loose cap, sterility compromised, discard.

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Injection-site redness, itching
  • Water retention, mild edema
  • Wrist / joint stiffness (carpal-tunnel-like)
  • Transient blood-glucose increase
  • Mild prolactin / cortisol increase (some peptides)

Contraindications · 5

  • Pregnancy and breastfeeding
  • Active malignancy
  • Known allergy to the peptide or its components
  • Severe hepatic or renal impairment (medical consultation required)
  • Age under 18

Related Peptides

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about CJC‑1295?

Reach out to an advisor on Telegram. We can help you find the right peptide.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.